多暴露评分、多基因评分与临床风险评分在2型糖尿病风险预测中的比较
研究基于英国生物银行356,621名无糖尿病且HbA1c正常的白人个体,构建纳入12种非遗传暴露的多暴露评分(PXS),并与多基因评分(PGS)及临床风险评分(CRS)比较。结果显示CRS的C统计量为0.839,高于PXS的0.762和PGS的0.709;PXS和PGS加入CRS可改善T2D分类准确性,但PXS仅提供适度增量预测价值。
要点
- CRS对2型糖尿病的预测能力优于PXS和PGS,C统计量分别为0.839、0.762和0.709。
- PXS最高10%人群的T2D风险是其余人群的5.90倍,CRS为9.97倍,PGS为2.00倍。
- PXS和PGS加入CRS可改善分类准确性,但PXS的增量预测价值仅为适度。
核心结论
- 对于2型糖尿病,PXS在已建立的临床风险因素基础上仅提供适度的增量预测价值。
- PXS概念在T2D风险分层中值得进一步考虑,并可能适用于其他慢性病风险预测模型。
研究设计与样本
- 从英国生物银行选取356,621名无既往T2D诊断且HbA1c正常的无亲缘关系白人英国裔个体。
- 使用自我报告和住院信息,通过机器学习从111个非遗传暴露和生活方式变量中选择预测因素构建PXS。
主要发现
- 研究人群中7,513人发生 incident T2D。
- PGS、PXS和CRS模型的C统计量分别为0.709、0.762和0.839。
- PGS、PXS和CRS最高10%个体的T2D风险分别是对应其余人群的2.00倍、5.90倍和9.97倍。
- PGS和PXS加入CRS后,病例的连续净重分类指数分别为15.2%和30.1%,对照分别为7.3%和16.9%。
临床怎么用
- 在临床风险评分基础上,可考虑联合PXS或PGS以改善T2D风险分类准确性。
- PXS的增量预测价值适中,暂不宜替代传统临床风险评分。
局限性
- 研究仅纳入白人英国裔个体,结果外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To establish a polyexposure score (PXS) for type 2 diabetes (T2D) incorporating 12 nongenetic exposures and examine whether a PXS and/or a polygenic risk score (PGS) improves diabetes prediction beyond traditional clinical risk factors. RESEARCH DESIGN AND METHODS: We identified 356,621 unrelated individuals from the UK Biobank of White British ancestry with no prior diagnosis of T2D and normal HbA1c levels. Using self-reported and hospital admission information, we deployed a machine learning procedure to select the most predictive and robust factors out of 111 nongenetically ascertained exposure and lifestyle variables for the PXS in prospective T2D. We computed the clinical risk score (CRS) and PGS by taking a weighted sum of eight established clinical risk factors and >6 million single nucleotide polymorphisms, respectively. RESULTS: In the study population, 7,513 had incident T2D. The C-statistics for the PGS, PXS, and CRS models were 0.709, 0.762, and 0.839, respectively. Individuals in the top 10% of PGS, PXS, and CRS had 2.00-, 5.90-, and 9.97-fold greater risk, respectively, compared to the remaining population. Addition of PGS and PXS to CRS improved T2D classification accuracy, with a continuous net reclassification index of 15.2% and 30.1% for cases, respectively, and 7.3% and 16.9% for controls, respectively. CONCLUSIONS: For T2D, the PXS provides modest incremental predictive value over established clinical risk factors. However, the concept of PXS merits further consideration in T2D risk stratification and is likely to be useful in other chronic disease risk prediction models.
引用
- He Y, Lakhani CM, Rasooly D, et al. Comparisons of Polyexposure, Polygenic, and Clinical Risk Scores in Risk Prediction of Type 2 Diabetes. Diabetes Care. 2021. PMID: 33563654. doi:10.2337/dc20-2049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。